权威指南+国际顶刊双重认证：参松养心降低房颤术后复发风险40%

Core Insights - The "Chinese Atrial Fibrillation Management Guidelines (2025)" was officially released, recommending the use of Cansong Yangxin capsules for paroxysmal atrial fibrillation patients either alone or in combination with traditional antiarrhythmic drugs to maintain sinus rhythm [1][2] - The guidelines highlight the high recurrence rates and safety concerns associated with atrial fibrillation treatments, emphasizing the need for safer and more effective strategies [1] Summary by Sections Treatment Recommendations - Cansong Yangxin capsules are recommended for maintaining sinus rhythm in paroxysmal atrial fibrillation, showing comparable effectiveness to Propafenone with better safety [2] - For patients with persistent atrial fibrillation undergoing catheter ablation, the combination of antiarrhythmic drugs and Cansong Yangxin significantly reduces the recurrence rate of atrial fibrillation [2] Clinical Challenges - Atrial fibrillation is the most common arrhythmia, with treatment challenges including high recurrence rates (30%-40% within one year post-ablation) and potential side effects from traditional antiarrhythmic drugs [1] - The guidelines stress that rhythm control is crucial for improving patient quality of life and delaying disease progression, yet significant challenges remain in clinical practice [1] Research and Development - The guidelines are based on multiple high-quality clinical studies, including the SS-CAT study, which confirmed the efficacy and safety of Cansong Yangxin capsules [2] - The SS-AFRF study demonstrated a 40% reduction in recurrence risk for patients with persistent atrial fibrillation after radiofrequency ablation when treated with Cansong Yangxin [2] Expert Commentary - The guidelines reflect a comprehensive accumulation of research and expert experience in atrial fibrillation prevention and management, showcasing the unique value of traditional Chinese medicine in this field [2]